메뉴 건너뛰기




Volumn 8, Issue SUPPL. 1, 2006, Pages 20-24

New lessons: Classic treatments, expanding options in ulcerative colitis

Author keywords

5 aminosalicyclic acid; Dosing regimens; Ulcerative colitis

Indexed keywords

BALSALAZIDE; BETA ALANINE; MESALAZINE; OLSALAZINE; SALAZOSULFAPYRIDINE; SULFAPYRIDINE;

EID: 33645472927     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/j.1463-1318.2006.00988.x     Document Type: Review
Times cited : (12)

References (20)
  • 1
    • 0008690916 scopus 로고
    • Cortisone in ulcerative colitis; final report on a therapeutic trial
    • Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955; 4947: 1041-8.
    • (1955) Br Med J , vol.4947 , pp. 1041-1048
    • Truelove, S.C.1    Witts, L.J.2
  • 2
    • 0025994645 scopus 로고
    • Incidence and prevalence of ulcerative colitis in Copenhagen county from 1962 to 1987
    • Langholz E, Munkholm P, Nielsen OH et al. Incidence and prevalence of ulcerative colitis in Copenhagen county from 1962 to 1987. Scand J Gastroenterol 1991; 26: 1247-56.
    • (1991) Scand J Gastroenterol , vol.26 , pp. 1247-1256
    • Langholz, E.1    Munkholm, P.2    Nielsen, O.H.3
  • 3
    • 3843109109 scopus 로고    scopus 로고
    • Ulcerative colitis practice guidelines in adults (update)
    • American College of Gastroenterology, Practice Parameters Committee
    • Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update). American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004; 99: 1371-85.
    • (2004) Am J Gastroenterol , vol.99 , pp. 1371-1385
    • Kornbluth, A.1    Sachar, D.B.2
  • 4
    • 2342445762 scopus 로고    scopus 로고
    • Management of inflammatory bowel disease
    • Nayar M, Rhodes JM. Management of inflammatory bowel disease. Postgrad Med J 2004; 80: 206-13.
    • (2004) Postgrad Med J , vol.80 , pp. 206-213
    • Nayar, M.1    Rhodes, J.M.2
  • 5
    • 4344602852 scopus 로고    scopus 로고
    • Guidelines for the management of inflammatory bowel disease in adults
    • Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53: V1-16.
    • (2004) Gut , vol.53
    • Carter, M.J.1    Lobo, A.J.2    Travis, S.P.3
  • 6
    • 84980093255 scopus 로고
    • The treatment of 124 cases of ulcerative colitis with salazapyrine and attempts at desensitization in cases of hypersensitivity to sulfa
    • Svartz N. The treatment of 124 cases of ulcerative colitis with salazapyrine and attempts at desensitization in cases of hypersensitivity to sulfa. Acta Med Scand 1948; 139: 465-72.
    • (1948) Acta Med Scand , vol.139 , pp. 465-472
    • Svartz, N.1
  • 7
    • 0030827118 scopus 로고    scopus 로고
    • A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis
    • Safdi M, DeMicco M, Sninsky C et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997; 92: 1867-71.
    • (1997) Am J Gastroenterol , vol.92 , pp. 1867-1871
    • Safdi, M.1    DeMicco, M.2    Sninsky, C.3
  • 8
    • 21044433011 scopus 로고    scopus 로고
    • Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: A randomised, double blind, placebo controlled study
    • Marteau P, Probert CS, Lindgren S et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: A randomised, double blind, placebo controlled study. Gut 2005; 54: 960-5.
    • (2005) Gut , vol.54 , pp. 960-965
    • Marteau, P.1    Probert, C.S.2    Lindgren, S.3
  • 9
    • 0034061366 scopus 로고    scopus 로고
    • A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis
    • Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 2000; 95: 1263-76.
    • (2000) Am J Gastroenterol , vol.95 , pp. 1263-1276
    • Cohen, R.D.1    Woseth, D.M.2    Thisted, R.A.3    Hanauer, S.B.4
  • 10
    • 0023521441 scopus 로고
    • Coated oral 5-aminosalicyclic acid therapy for mildly to moderately active ulcerative colitis. A randomized study
    • Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicyclic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317: 1625-9.
    • (1987) N Engl J Med , vol.317 , pp. 1625-1629
    • Schroeder, K.W.1    Tremaine, W.J.2    Ilstrup, D.M.3
  • 11
  • 12
    • 8844258136 scopus 로고    scopus 로고
    • Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease
    • Klotz U, Schwab M. Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease. Ad Drug Deliv Rev 2005; 57: 267-79.
    • (2005) Ad Drug Deliv Rev , vol.57 , pp. 267-279
    • Klotz, U.1    Schwab, M.2
  • 14
    • 33645472846 scopus 로고    scopus 로고
    • Salazopyrin Summary of Product Characteristics (SmPC)
    • Salazopyrin Summary of Product Characteristics (SmPC). 2004.
    • (2004)
  • 15
    • 33645464770 scopus 로고    scopus 로고
    • Asacol® Summary of Product Characteristics (SmPC)
    • Asacol® Summary of Product Characteristics (SmPC). 2003.
    • (2003)
  • 16
    • 33645462936 scopus 로고    scopus 로고
    • An analysis of factors that influence selection of the induction dose of delayed-release oral mesalamine (Asacol) in ulcerative colitis in the community setting
    • Poster and Abstract, R.0469. [WWW document] URL (accessed February 2005)
    • Sands BE, Bloomfeld RS, Sandborn WJ et al. An analysis of factors that influence selection of the induction dose of delayed-release oral mesalamine (Asacol) in ulcerative colitis in the community setting. World Congress of Gastroenterology 2005. Poster and Abstract, R.0469. [WWW document] URL http://www.pulsus.com/search.cfm. (accessed February 2005).
    • (2005) World Congress of Gastroenterology
    • Sands, B.E.1    Bloomfeld, R.S.2    Sandborn, W.J.3
  • 17
    • 25144473178 scopus 로고    scopus 로고
    • Delayed-release oral mesalamine 4.8g/day (800mg tablet) versus 2.4g/day (400mg tablet) for treatment of moderately active ulcerative colitis: Combined analysis of two randomized, double-blind, controlled trials
    • Hanauer SB, Sandborn WJ, Kornbluth A, Hardi R, Regalli G, Yeh C. Delayed-release oral mesalamine 4.8g/day (800mg tablet) versus 2.4g/day (400mg tablet) for treatment of moderately active ulcerative colitis: Combined analysis of two randomized, double-blind, controlled trials. Gastroenterology 2005; 128: A74-A75.
    • (2005) Gastroenterology , vol.128
    • Hanauer, S.B.1    Sandborn, W.J.2    Kornbluth, A.3    Hardi, R.4    Regalli, G.5    Yeh, C.6
  • 18
    • 33645466493 scopus 로고    scopus 로고
    • Delayed-release oral mesalamine 4.8g/day (800mg tablet) versus 2.4g/day (400mg tablet) for treatment of moderately active ulcerative colitis: Combined efficacy analysis of two randomized, double-blind, controlled trials
    • Poster and Abstract, R.0470. [WWW document] URL (accessed February 2005)
    • Hanauer SB, Sandborn WJ, Kornbluth A, Hardi R, Regalli G, Yeh C. Delayed-release oral mesalamine 4.8g/day (800mg tablet) versus 2.4g/day (400mg tablet) for treatment of moderately active ulcerative colitis: combined efficacy analysis of two randomized, double-blind, controlled trials. World Congress of Gastroenterology. Poster and Abstract, R.0470. [WWW document] URL http://www.pulsus.com/search.cfm. (accessed February 2005).
    • World Congress of Gastroenterology
    • Hanauer, S.B.1    Sandborn, W.J.2    Kornbluth, A.3    Hardi, R.4    Regalli, G.5    Yeh, C.6
  • 19
    • 33645462863 scopus 로고    scopus 로고
    • Combined subgroup analyses of two randomized, double-blind, controlled trials: Delayed-release oral mesalamine 4.8g/day (800 mg tablet) versus 2.4g/day (400 mg tablet) for treatment of moderately active ulcerative colitis: Combined efficacy analysis of two randomized, double-blind, controlled trials
    • Poster and Abstract, R.0468. [WWW document] URL (accessed February 2005)
    • Sandborn WJ, Hanauer SB, Katz S et al. Combined subgroup analyses of two randomized, double-blind, controlled trials: Delayed-release oral mesalamine 4.8g/day (800 mg tablet) versus 2.4g/day (400 mg tablet) for treatment of moderately active ulcerative colitis: Combined efficacy analysis of two randomized, double-blind, controlled trials. World Congress of Gastroenterology. Poster and Abstract, R.0468. [WWW document] URL http://www.pulsus.com/search.cfm. (accessed February 2005).
    • World Congress of Gastroenterology
    • Sandborn, W.J.1    Hanauer, S.B.2    Katz, S.3
  • 20
    • 33645466728 scopus 로고    scopus 로고
    • Safety of delayed-release oral mesalamine 4.8g/day (800mg tablet) compared to 2.4g/day (400mg tablet) for treatment of active ulcerative colitis: Analysis of combined data from two randomized, double-blind, controlled trials
    • Poster and Abstract, R.0471. [WWW document] URL (accessed February 2005)
    • Hanauer SB, Loftus EV, Binion DG, Gordon GL, Smith-Hall N, Law L. Safety of delayed-release oral mesalamine 4.8g/day (800mg tablet) compared to 2.4g/day (400mg tablet) for treatment of active ulcerative colitis: analysis of combined data from two randomized, double-blind, controlled trials. World Congress of Gastroenterology. Poster and Abstract, R.0471. [WWW document] URL http://www.pulsus.com/search.cfm. (accessed February 2005).
    • World Congress of Gastroenterology
    • Hanauer, S.B.1    Loftus, E.V.2    Binion, D.G.3    Gordon, G.L.4    Smith-Hall, N.5    Law, L.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.